Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone

Stock Track

03/31

IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.

The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.

The drug candidate works by blocking the "don't eat me" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1139291031"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139291031\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139291031?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139291031","market":"nz","top_or_hot":-1,"title":"Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone","media":"Stock Track","content":"<p>IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.</p><p>The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.</p><p>The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-31 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.</p><p>The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.</p><p>The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1139291031","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139291031","pubTimestamp":1774922528,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"个股追踪|IMMUNEONCO-B盘中大涨5.15%三期临床试验里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.The biopharmaceutical company announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306 is described as the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development.The drug candidate works by blocking the \"don't eat me\" signal through inhibition of CD47-SIRPα interaction while enhancing interactions to activate immune cells. It preferentially binds to CD20 over CD47, aiming to effectively eliminate malignant B cells with minimized toxicity. The company holds global intellectual property and commercialization rights for IMM0306.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}